A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

被引：0
|
作者：
Nikol Snoeren
Emile E Voest
Andre M Bergman
Otilia Dalesio
Henk M Verheul
Rob AEM Tollenaar
Joost RM van der Sijp
Sander B Schouten
Inne HM Borel Rinkes
R van Hillegersberg
机构：
[1] University Medical Center Utrecht,Department of Surgical Oncology
[2] University Medical Center Utrecht,Department of Medical Oncology
[3] Antonie van Leeuwenhoek Hospital,Department of Medical Oncology
[4] Antonie van Leeuwenhoek Hospital,Department of Biometrics
[5] VU Medical Center De Boelelaan 1117,Department of Medical Oncology
[6] Department of Surgery,undefined
[7] Leiden,undefined
[8] Department of Surgery,undefined
来源：
BMC Cancer | / 10卷
关键词：
Vascular Endothelial Growth Factor; Bevacizumab; Liver Metastasis; Disease Free Survival; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 29 条
  • [1] Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study
    Snoeren, Nikol
    van Hillegersberg, Richard
    Schouten, Sander B.
    Bergman, Andre M.
    van Werkhoven, Erikv
    Dalesio, Otilia
    Tollenaar, Rob A. E. M.
    Verheul, Henk M.
    van der Sijp, Joost
    Rinkes, Inne H. M. Borel
    Voest, E. E.
    NEOPLASIA, 2017, 19 (02): : 93 - 99
  • [2] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    Dewdney, A.
    Cunningham, D.
    Barbachano, Y.
    Chau, I.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1718 - 1721
  • [3] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    A Dewdney
    D Cunningham
    Y Barbachano
    I Chau
    British Journal of Cancer, 2012, 106 : 1718 - 1721
  • [4] Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
    Nakayama, Goro
    Mitsuma, Ayako
    Sunagawa, Yuki
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Matsui, Takanori
    Nakayama, Hiroshi
    Nakata, Kazuhiko
    Ishiyama, Akiharu
    Asada, Takahiro
    Umeda, Shinichi
    Ezaka, Kazuhiro
    Hattori, Norifumi
    Takami, Hideki
    Kobayashi, Daisuke
    Tanaka, Chie
    Kanda, Mitsuro
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    ONCOLOGIST, 2018, 23 (08) : 919 - 927
  • [5] A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
    Wong, R.
    Cunningham, D.
    Barbachano, Y.
    Saffery, C.
    Valle, J.
    Hickish, T.
    Mudan, S.
    Brown, G.
    Khan, A.
    Wotherspoon, A.
    Strimpakos, A. S.
    Thomas, J.
    Compton, S.
    Chua, Y. J.
    Chau, I.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2042 - 2048
  • [6] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
    Hoff, Paulo M.
    Hochhaus, Andreas
    Pestalozzi, Bernhard C.
    Tebbutt, Niall C.
    Li, Jin
    Kim, Tae Won
    Koynov, Krassimir D.
    Kurteva, Galina
    Pinter, Tamas
    Cheng, Ying
    van Eyll, Brigitte
    Pike, Laura
    Fielding, Anitra
    Robertson, Jane D.
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603
  • [7] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
    Dimitrios Pectasides
    Vasilios Karavasilis
    George Papaxoinis
    Georgia Gourgioti
    Thomas Makatsoris
    Georgia Raptou
    Eleni Vrettou
    Joseph Sgouros
    Epaminontas Samantas
    George Basdanis
    Pavlos Papakostas
    Dimitrios Bafaloukos
    Vassiliki Kotoula
    Haralambos P. Kalofonos
    Chrisoula D. Scopa
    George Pentheroudakis
    George Fountzilas
    BMC Cancer, 15
  • [8] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
    Pectasides, Dimitrios
    Karavasilis, Vasilios
    Papaxoinis, George
    Gourgioti, Georgia
    Makatsoris, Thomas
    Raptou, Georgia
    Vrettou, Eleni
    Sgouros, Joseph
    Samantas, Epaminontas
    Basdanis, George
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Kotoula, Vassiliki
    Kalofonos, Haralambos P.
    Scopa, Chrisoula D.
    Pentheroudakis, George
    Fountzilas, George
    BMC CANCER, 2015, 15
  • [9] Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy
    Kakolyris, S.
    Souglakos, J.
    Polyzos, A.
    Ardavanis, A.
    Ziras, N.
    Athanasiadis, A.
    Varthalitis, I.
    Amarantidis, K.
    Tsousis, S.
    Vamvakas, L.
    Vardakis, N.
    Georgoulias, V.
    ONCOLOGY, 2008, 74 (1-2) : 31 - 36
  • [10] Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial
    Chen, Hong-Hwa
    Lin, Jen-Kou
    Chen, Joe-Bin
    Chuang, Chieh-Han
    Liu, Mei-Ching
    Wang, Jen-Yi
    Changchien, Chung-Rong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (01) : 61 - 68
123